Valuation: Alar Pharmaceuticals Inc.

Market Cap 5.91B 182M 162M 150M 136M 256M 17.2B 259M 1.8B 707M 9.04B 684M 669M 28.8B P/E 2024
524x
P/E 2025 -255x
Enterprise Value 3.62B 112M 99.4M 92.03M 83.29M 157M 10.53B 159M 1.1B 433M 5.53B 418M 410M 17.63B EV / Sales 2024
1,207x
EV / Sales 2025 6,544x
Free-Float
58.96%
Yield 2024
0.18%
Yield 2025 0.03%
08-28 UAE Accepts Alar's Patent Acceptance for Long-Acting Ketamine Injectable Formulations MT
08-10 Alar Pharmaceuticals Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 CI
05-08 Alar Pharmaceuticals Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 CI
04-06 Alar breaks key barriers in ketamine therapy with positive Phase 1 results for long-acting injectable Ala-3000 for treatment-resistant depression RE
04-06 Alar Pharmaceuticals Inc Announces Positive Phase 1 Results For Long-Acting Injectable ALA-3000 For Treatment-Resistant Depression CI
03-16 Alar Pharmaceuticals Inc Announces Buprenorphine Injectable ALA-1000 Demonstrates Long-Term Efficacy And Favorable Safety Profile In Canine Osteoarthritis Pain Management CI
03-16 Alar Pharmaceuticals Inc announces positive results for Ala-1000 in canine osteoarthritis study RE
03-12 Alar Pharmaceuticals Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 CI
03-02 Alar Pharmaceuticals Inc. announces Annual dividend, payable on September 14, 2026 CI
12-30 Alar Pharmaceuticals Inc. Announces Submission of New Animal Drug Application to APHIA for Long-Acting Osteoarthritis Analgesic, Bupanlar CI
11-10 Alar Pharmaceuticals Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025 CI
09/10/25 IMPI approves Alar's long-acting injectable formulations of ketamine pamoate salts patent RE
07/08/25 Alar Pharmaceuticals Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025 CI
1 day+2.67%
1 week+4.12%
Current month-6.94%
1 month-10.61%
3 months-19.55%
6 months-47.94%
Current year-70.89%
1 week 81.1
Extreme 81.1
93
1 month 81.1
Extreme 81.1
101
Current year 81.1
Extreme 81.1
313
1 year 81.1
Extreme 81.1
317
3 years 81.1
Extreme 81.1
465
5 years 42.8
Extreme 42.8
465
10 years 42.8
Extreme 42.8
465
Manager TitleAgeSince
Chief Executive Officer - 22/09/2016
Director of Finance/CFO - 15/10/2019
Director TitleAgeSince
Chairman - 22/09/2016
Director/Board Member - 22/09/2016
Director/Board Member - 06/08/2018
Change 5-day change 1-year change 3-year change Capi.($)
+2.67%+4.12%-69.48%-56.40% 176M
-0.90%+5.10%+58.89%+120.31% 1,144B
-1.26%+0.90%+33.52%+69.23% 625B
-2.02%-0.01%+22.50%+95.85% 511B
+0.54%+5.69%+39.60%+65.02% 377B
+0.21%+0.92%+69.74%+43.90% 366B
+0.30%+3.44%+21.35%+50.15% 291B
-0.03%+2.55%+1.12%+24.89% 262B
-0.54%+2.42%+44.93%+59.83% 237B
-2.03%-0.45%+23.19%+97.08% 194B
Average -0.29%+6.33%+24.54%+56.99% 400.81B
Weighted average by Cap. -0.74%+6.91%+40.41%+81.00%

Financials

2024 2025
Net sales 5.82M 179K 160K 148K 134K 252K 16.92M 255K 1.77M 696K 8.89M 673K 659K 28.34M 2.75M 84.86K 75.62K 70.01K 63.36K 119K 8.01M 121K 839K 329K 4.21M 318K 312K 13.41M
Net income 18.17M 560K 499K 462K 418K 788K 52.85M 797K 5.54M 2.17M 27.78M 2.1M 2.06M 88.53M -79.68M -2.46M -2.19M -2.03M -1.83M -3.45M -232M -3.5M -24.3M -9.53M -122M -9.21M -9.02M -388M
Net Debt -2.43B -74.92M -66.76M -61.81M -55.93M -105M -7.07B -107M -741M -291M -3.72B -281M -275M -11.84B -2.29B -70.67M -62.98M -58.31M -52.77M -99.41M -6.67B -101M -699M -274M -3.51B -265M -260M -11.17B
Projected Income Statement - Annual - Alar Pharmaceuticals Inc.
Logo Alar Pharmaceuticals Inc.
Alar Pharmaceuticals Inc is a Taiwan-based company mainly engaged in the research and development of new drugs. The Company mainly develops long-acting drugs for the treatment of opioid use disorder, treatment-resistant depression, and Parkinson disease. The main products include ALA-1000, buprenorphine subcutaneous long-acting sustained-release injection, is indicated for indicated for opioid use disorder (OUD); ALA-1300, subcutaneous injection, is indicated for opioid addiction; ALA-3000, ketamine subcutaneous long-acting sustained-release injection, is indicated for treatment-resistant depression (TRD); ALA-4000, apomorphine subcutaneous long-acting sustained-release injection, is indicated for Parkinson disease (PD); and ALA-2000, subcutaneous injection, is indicated for alcohol addiction and opioid use disorder. The Company distributes ALA-1000 and related products to the United States, France, Germany, the United Kingdom, Italy, and Japan markets.
Employees
-
Date Price Change Volume
20/10/26 NT$88.50 +2.67% 84,843
20/10/26 NT$86.20 -0.23% 26,056
19/10/26 NT$86.40 +0.82% 26,987
16/10/26 NT$85.70 +3.13% 49,393
15/10/26 NT$83.10 -1.89% 71,781

Annual profits - Rate of surprise

Rate of surprise - EPS - Annual - Alar Pharmaceuticals Inc.
  1. Stock Market
  2. Stocks
  3. 6785 Stock